A pilot study of oral idarubicin in metastatic melanoma.
Seventeen patients with disseminated melanoma were treated with Idarubicin (IDA) at the dose of 15 mg/m2 daily for 3 consecutive days every 4 weeks by oral route. One complete remission and one partial remission were achieved (remission rate: 12%). The treatment was well tolerated. We conclude that oral IDA may be considered for a pilot trial in a regimen of combination therapy in patients with metastatic melanoma.
Martoni
A
A
Pacciarini
M A
MA
Piana
E
E
Pannuti
F
F
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D003630:Daunorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015255:Idarubicin; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged
D000903:Antibiotics, Antineoplastic; D015255:Idarubicin; D003630:Daunorubicin